Tau and Amyloid-β Peptides in Serum of Patients With Parkinson's Disease: Correlations With CSF Levels and Clinical Parameters
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Tau and Amyloid-β Peptides in Serum of Patients With Parkinson's Disease: Correlations With CSF Levels and Clinical Parameters
Authors
Keywords
-
Journal
Frontiers in Neurology
Volume 13, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2022-02-25
DOI
10.3389/fneur.2022.748599
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Tau in the Pathophysiology of Parkinson’s Disease
- (2021) Lina Pan et al. JOURNAL OF MOLECULAR NEUROSCIENCE
- Increase of Prokineticin‐2 in Serum of Patients with Parkinson's Disease
- (2021) Tommaso Schirinzi et al. MOVEMENT DISORDERS
- Young onset and late onset Parkinson’s disease exhibit a different profile of fluid biomarkers and clinical features.
- (2020) Tommaso Schirinzi et al. NEUROBIOLOGY OF AGING
- An update on blood-based biomarkers for non-Alzheimer neurodegenerative disorders
- (2020) Nicholas J. Ashton et al. Nature Reviews Neurology
- Amyloid-β42/Neurogranin Ratio as a Potential Index for Cognitive Impairment in Parkinson’s Disease
- (2020) Giulia Maria Sancesario et al. JOURNAL OF ALZHEIMERS DISEASE
- CSF and blood biomarkers for Parkinson's disease
- (2019) Lucilla Parnetti et al. LANCET NEUROLOGY
- Systemic activation of Nrf2 pathway in Parkinson's disease
- (2019) Sara Petrillo et al. MOVEMENT DISORDERS
- Relationship between cerebrospinal fluid biomarkers and structural brain network properties in Parkinson's disease
- (2018) Nooshin Abbasi et al. MOVEMENT DISORDERS
- Disease Modification in Parkinson's Disease: Current Approaches, Challenges, and Future Considerations
- (2018) Anthony E. Lang et al. MOVEMENT DISORDERS
- White paper by the Society for CSF Analysis and Clinical Neurochemistry: Overcoming barriers in biomarker development and clinical translation
- (2018) Charlotte E. Teunissen et al. Alzheimers Research & Therapy
- CSF α-synuclein inversely correlates with non-motor symptoms in a cohort of PD patients
- (2018) Tommaso Schirinzi et al. PARKINSONISM & RELATED DISORDERS
- Levels of amyloid-beta-42 and CSF pressure are directly related in patients with Alzheimer’s disease
- (2017) Tommaso Schirinzi et al. JOURNAL OF NEURAL TRANSMISSION
- Association of Plasma Aβ40 Peptides, But Not Aβ42, with Coronary Artery Disease and Diabetes Mellitus
- (2016) Benjamin Roeben et al. JOURNAL OF ALZHEIMERS DISEASE
- The Clinical Use of Cerebrospinal Fluid Biomarkers for Alzheimer’s Disease Diagnosis: The Italian Selfie
- (2016) Giulia M. Sancesario et al. JOURNAL OF ALZHEIMERS DISEASE
- Progression of Regional Microstructural Degeneration in Parkinson’s Disease: A Multicenter Diffusion Tensor Imaging Study
- (2016) Yu Zhang et al. PLoS One
- Plasma β-amyloid in Alzheimer’s disease and vascular disease
- (2016) Shorena Janelidze et al. Scientific Reports
- How many biomarkers to discriminate neurodegenerative dementia?
- (2015) Giulia M. Sancesario et al. CRITICAL REVIEWS IN CLINICAL LABORATORY SCIENCES
- Aβ42 and Aβ40: similarities and differences
- (2015) Tian Qiu et al. JOURNAL OF PEPTIDE SCIENCE
- A Clinical and Biochemical Analysis in the Differential Diagnosis of Idiopathic Normal Pressure Hydrocephalus
- (2015) Tommaso Schirinzi et al. Frontiers in Neurology
- Plasma exosomal α-synuclein is likely CNS-derived and increased in Parkinson’s disease
- (2014) Min Shi et al. ACTA NEUROPATHOLOGICA
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More